CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 180,100 shares, a drop of 32.9% from the February 28th total of 268,500 shares. Based on an average daily trading volume, of 630,700 shares, the short-interest ratio is presently 0.3 days. Currently, 6.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CNSP. Connective Capital Management LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth about $34,000. Citadel Advisors LLC acquired a new position in shares of CNS Pharmaceuticals in the 4th quarter valued at approximately $39,000. Jane Street Group LLC lifted its holdings in shares of CNS Pharmaceuticals by 1,712.3% during the 4th quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock worth $51,000 after acquiring an additional 396,577 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth approximately $30,000. Finally, XTX Topco Ltd bought a new position in CNS Pharmaceuticals in the fourth quarter valued at approximately $36,000. Institutional investors own 14.02% of the company’s stock.

CNS Pharmaceuticals Price Performance

CNS Pharmaceuticals stock traded down $0.02 during mid-day trading on Friday, reaching $1.30. 161,488 shares of the company were exchanged, compared to its average volume of 276,800. The firm has a market cap of $1.50 million, a PE ratio of -0.02 and a beta of 2.65. The company has a fifty day simple moving average of $3.86 and a 200-day simple moving average of $5.33. CNS Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $965.00.

Analyst Upgrades and Downgrades

CNSP has been the subject of a number of recent research reports. Maxim Group reissued a “hold” rating on shares of CNS Pharmaceuticals in a research report on Tuesday. Alliance Global Partners raised shares of CNS Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 24th.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.